fbpx

EMERGERS

Equity Research of
Nordic Growth Companies

Home

Författare: johan@emergers.se

QLUCORE: Structural growth story on track with a slight expansion of long-term scope

2022-11-30• Analys, Research

After the strong growth in Q1’22/23, sales bounced back in Q2’22/23, right in line with our forecast. With the process to CE marking of...

Read More →

KEBNI: New targets reflect high conviction in strong growth across the board in 2023-2027

2022-11-24• Analys, Research

The announcement of KebNi’s revised strategy and financial targets for 2023-2027 reflect a firm conviction in steady long term growth...

Read More →

KEBNI: On track to scale up in 2023

2022-11-18• Analys, Research

KebNi’s Q3-report provided some further insight into the progress made in setting up volume series production within Inertial Sensing,...

Read More →

SIMRIS ALG: Ready to execute on a three-pronged roadmap to capture the most high-value opportunities

2022-11-11• Analys, Research

Following the successful acquisition of Cyano Biotech GmbH in Q3, Simris is now moving forward with a three-pronged approach to value...

Read More →

DLABORATORY: Strong growth and positive EBITDA a welcome shift in pace

2022-11-04• Analys, Research

With a steep increase in revenue, 35% recurring revenue growth, turn to positive EBITDA of SEK 2.2m and a forward-leaning statement from...

Read More →

TRADING IDEA – Short DAX – Stage set for a pullback   

2022-10-27• TRADING IDEA

Image credit: TradingView Trading idea – Short DAX – Stage set for a pullback    After the strength seen across the...

Read More →

NANEXA: Charging to enter triple clinical trials in the coming year

2022-10-26• Analys, Research

Besides starting its third proprietary development project in Q2 (NEX-22, a long-acting formulation of liraglutide for treatment of type 2...

Read More →

KEBNI: Saab order the portal to next level for KebNi

2022-10-17• Analys, Research

With the SEK 76m volume order for IMUs from Saab, KebNi now enters the next level of monetising its IMU technology. The order however only...

Read More →

GRANGEX: Upwards revision of reserves accompanied by strong macro backdrop

2022-09-21• Analys, Research

GRÄNGESBERG EXPLORATION The ongoing preparations for the DFS of Dannemora has now yielded its second upwards revision, a 16% increase in...

Read More →

NANEXA: New project NEX-22 to add significant daily benefits for 50m patient market

2022-09-16• Analys, Research

Nanexa’s next proprietary development project, NEX-22, is a long-acting formulation of liraglutide for treatment of type 2 diabetes...

Read More →

Actionable Investment Research | Sectors & Themes | Shorts and Frauds

Widmark Research 

CONTACT

Johan Widmark

Mail: johan@emergers.se
Tel: +46739196641

Östermalmsgatan 26A
114 26 Stockholm, Sweden

For new research on growth stocks, sign up to our newsletter